Sagimet Biosciences (NASDAQ:SGMT) used an investor discussion at Oppenheimer’s 36th Annual Healthcare Life Sciences ...
Viking Therapeutics, Inc. stock has spiked over 200% this year after positive obesity data from its Phase 2 clinical study of drug candidate VK2735, a GLP-1 agonist, in weight loss. Viking stock has ...
ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, ...
The MarketWatch News Department was not involved in the creation of this content. Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and ...
Please provide your email address to receive an email when new articles are posted on . Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, ...
Altimmune Inc. (NASDAQ: ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide. Patients had metabolic dysfunction-associated steatohepatitis (MASH) at 48 weeks. MASH is a ...
Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026 /PRNewswire ...
In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue ...
Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results